Dinalbuphine sebacate

Overview

Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Postoperative Pain Management on Patients Undergoing Lung Tumor Resection	2024/05/03	NCT06397807	N/A	Not yet recruiting	China Medical University Hospital
A Novel, Potent and Non-addictive Analgesic of Combinations for Knee Replacement Moderate to Severe Pain Management	2023/05/06	NCT05842733	Phase 2	ENROLLING_BY_INVITATION	Sinew Pharma Inc.
Postoperative Pain Management on Uvulopalatopharyngoplasty Patients	2023/04/24	NCT05825495	Phase 4	Not yet recruiting	Li-Jen Hsin
Naldebain® Extended-release Injection After Cesarean Section in Pain Management	2022/07/06	NCT05446311	N/A	UNKNOWN	Tri-Service General Hospital
Postoperative Pain Management of Caesarean Section	2021/08/18	NCT05009771	N/A	Recruiting	Mackay Memorial Hospital
Naldebain for Pain Management of Laparoscopic Cholecystectomy	2021/03/22	NCT04808544	Phase 2	Completed	E-DA Hospital
Naldebain for Pain Control After Bariatric Surgery	2020/12/03	NCT04651361	Phase 2	UNKNOWN	E-DA Hospital
A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.	2020/02/05	NCT04256434	Phase 1	Completed	Lumosa Therapeutics Co., Ltd.
NALDEBAIN for Postoperative Pain Management in Take Down of Anastomosis	2019/02/26	NCT03854851	Phase 4	UNKNOWN	China Medical University Hospital
Comparison of the Efficacy and Safety of NALDEBAIN With Conventional Treatment After Laparoscopic Cholecystectomy	2018/10/19	NCT03713216	Phase 4	Completed	Cathay General Hospital

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
NALDEBAIN® EXTENDED RELEASE INJECTION 75MG/ML	Hsinchu Plant of UBI Pharma Inc.	SIN16058P	INJECTION, SOLUTION	75mg/ ml	12/15/2020

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access